Abstract
Background
Unfractionated heparin has largely been replaced by low molecular weight heparin in the treatment and prevention of thrombosis and recurrent miscarriage in pregnancy. There is little information, however, about the efficacy and safety of tinzaparin, which has the advantage of being administered as a single daily dose.
Aims
To evaluate the safety and efficacy of tinzaparin use in pregnancy.
Methods
We retrospectively reviewed the medical records of women who were prescribed tinzaparin during pregnancy and the puerperium in our hospitals from January 2000 to December 2008. Tinzaparin was given as a single daily prophylactic dose for women with a history of venous thromboembolism (VTE) or recurrent miscarriage and as a single daily therapeutic dose for women diagnosed with VTE. The primary outcomes recorded were thrombosis, bleeding, allergy and thrombocytopenia.
Results
One hundred and forty-nine women aged between 17 and 44 years received tinzaparin in pregnancy and the puerperium over the study period. The dose administered was therapeutic in 21 (14 %) cases and prophylactic in all others. VTE recurred in three women who had a history of VTE (3.6 %). Antepartum and postpartum haemorrhage occurred in 9.7 and 5 % of cases, respectively and two women developed thrombocytopenia but their platelets remained above 100,000/ml. Fifty-seven women (38 %) had regional anaesthesia without complication.
Conclusion
Our study demonstrates a safety profile for tinzaparin in pregnancy that is equivalent to other low molecular weight heparins with the advantage of single daily dosing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenkranz A, Hiden M, Leschnik B et al (2008) Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 99(2):331–337
Centre for Maternal and Child Enquiries (CMACE) (2011) Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 118 (Suppl 1):1–203
Chang J, Elam-Evans LD, Berg CJ et al. (2003) Pregnancy-related mortality surveillance-United States, 1991–1999. MMWR Surveill Summ 52(2):1–8
Flessa HC, Kapstrom AB, Glueck HI et al (1965) Placental transport of heparin. Am J Obstet Gynecol 93:570–573
Harenberg J, Schneider D, Heilmann L et al (1993) Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 23:314–320
Bates SM, Greer IA, Middeldorp S et al (2012) (2012) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl 2):e691S–e736S
Van Dongen CJ, van den Belt AG, Prins MH et al. (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (4):CD001100. Review
Sanson BJ, Lensing AWA, Prins MH et al (1999) Safety of LMWH in pregnancy: a systematic review. ThrombHaemost 81:668–672
Royal College of Obstetrics and Gynaecology Green Top Guideline Number 37
Marik PE, Plante LA (2008) Venous thromboembolic disease and pregnancy. N Engl J Med 359(19):2025–2033
Smith MP, Norris LA, Steer PJ et al (2004) Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 190(2):495–501
Ní Ainle F, Wong A, Appleby N et al (2008) Efficacy and safety of once daily LMWH (Tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 19(7):689–692
Nelson-Piercy C, Powrie R, Borg JY et al (2011) Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol 159(2):293–299
Thromboprophylaxis During Pregnancy, Labour and after Vaginal Delivery. GreenTop Guideline 37
Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28:172–197
Ogden CL, Carroll MD, Kit BK et al (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307(5):483–490
Hayes-Ryan D, Byrne BM (2012) Prevention of thrombosis in pregnancy: how practical are consensus derived clinical practice guidelines? J Obstet Gynaecol 32:740–742
Greer IA, Nelson-Piercy C (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106(2):401–407
Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K et al (2002) Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 100:1060–1062
Donnelly J, Murphy K, McAuliffe F (2012) Obstetric outcome with low molecular weight heparin therapy during pregnancy. IMJ 105(1):27–29
Wang Peng, Xin Xiao-tang, La Hai et al (2011) Spontaneous cervical epidural hematoma during pregnancy: case report and literature review. Eur Spine J 20(Suppl 2):S176–S179
Lutomski JE, Byrne BM, Devane D, Greene RA (2012) Increasing trends in atonic postpartum haemorrhage in Ireland: an 11 year population-based cohort study. BJOG 119:306–314
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khalifeh, A., Grantham, J., Byrne, J. et al. Tinzaparin safety and efficacy in pregnancy. Ir J Med Sci 183, 249–252 (2014). https://doi.org/10.1007/s11845-013-0998-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-013-0998-7